title: HER2-positive breast cancer: a new piece of the puzzle.
authors.affiliation: Department of Surgery, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria. Electronic address: michael.gnant@meduniwien.ac.at.
authors.forename: Michael
authors.initials: M
authors.lastname: Gnant
authors.affiliation: Department of Internal Medicine I, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria.
authors.forename: Rupert
authors.initials: R
authors.lastname: Bartsch
authors.affiliation: Department of Internal Medicine I, Breast Health Center, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria.
authors.forename: Guenther G
authors.initials: GG
authors.lastname: Steger
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008453:Maytansine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D000068878:Trastuzumab
chemical_list: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human